武田的维多珠单抗在国内获批,用于治疗中度至重度活动性溃疡性结肠炎和克罗恩病

2020-03-25 MedSci原创 MedSci原创

维多珠单抗是一种人源化单克隆抗体,设计用于特异性拮抗α4β7整联蛋白,从而抑制α4β7整联蛋白与肠粘膜地址素细胞粘附分子1(MAdCAM-1)的结合。

武田制药宣布其Entyvio(维多珠单抗)经中国药品监督管理局(NMPA)批准,用于治疗中度至重度活动性溃疡性结肠炎(UC)或克罗恩病(CD)的成年患者。这些患者对常规疗法或肿瘤坏死因子α(TNF-α)抑制剂的反应不足或不耐受。

武田中国总裁Sean Shan说:"非常感谢NMPA正式批准Entyvio用于中国患者的治疗。该批准为临床医生带来了更多的治疗选择,并使更多的IBD患者能够恢复正常的生活。"

溃疡性结肠炎(UC)和克罗恩氏病(CD)是最常见的两种炎症性肠病(IBD)。UC和CD都是胃肠道的慢性且具有复发性的炎症疾病。UC仅涉及大肠,而CD则可能影响从口腔到肛门的任何部分。UC通常表现为腹部不适,肠蠕动松弛。CD通常表现出腹痛,腹泻和体重减轻的症状。UC或CD的原因尚不完全清楚。

维多珠单抗是一种人源化单克隆抗体,设计用于特异性拮抗α4β7整联蛋白,抑制α4β7整联蛋白与肠粘膜地址素细胞粘附分子1(MAdCAM-1)的结合。维多珠单抗通过抑制α4β7整联蛋白,可以限制炎症细胞向肠道组织的浸润。

原始出处:

https://www.firstwordpharma.com/node/1709962?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1695156, encodeId=ad221695156b6, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Aug 09 06:41:35 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723996, encodeId=e5a81e2399603, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Wed Jan 27 19:41:35 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717372, encodeId=bce51e173721a, content=<a href='/topic/show?id=2178651e5ec' target=_blank style='color:#2F92EE;'>#活动性溃疡性结肠炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65175, encryptionId=2178651e5ec, topicName=活动性溃疡性结肠炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=462a32388178, createdName=chg132, createdTime=Sat Apr 04 02:41:35 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796923, encodeId=96011e9692355, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 10 05:41:35 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810861, encodeId=08341810861ac, content=<a href='/topic/show?id=ee008640309' target=_blank style='color:#2F92EE;'>#至重度活动性溃疡性结肠炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86403, encryptionId=ee008640309, topicName=至重度活动性溃疡性结肠炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Jan 25 08:41:35 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517253, encodeId=3510151e253df, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Fri Mar 27 09:41:35 CST 2020, time=2020-03-27, status=1, ipAttribution=)]
    2020-08-09 nymo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1695156, encodeId=ad221695156b6, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Aug 09 06:41:35 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723996, encodeId=e5a81e2399603, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Wed Jan 27 19:41:35 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717372, encodeId=bce51e173721a, content=<a href='/topic/show?id=2178651e5ec' target=_blank style='color:#2F92EE;'>#活动性溃疡性结肠炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65175, encryptionId=2178651e5ec, topicName=活动性溃疡性结肠炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=462a32388178, createdName=chg132, createdTime=Sat Apr 04 02:41:35 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796923, encodeId=96011e9692355, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 10 05:41:35 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810861, encodeId=08341810861ac, content=<a href='/topic/show?id=ee008640309' target=_blank style='color:#2F92EE;'>#至重度活动性溃疡性结肠炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86403, encryptionId=ee008640309, topicName=至重度活动性溃疡性结肠炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Jan 25 08:41:35 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517253, encodeId=3510151e253df, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Fri Mar 27 09:41:35 CST 2020, time=2020-03-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1695156, encodeId=ad221695156b6, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Aug 09 06:41:35 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723996, encodeId=e5a81e2399603, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Wed Jan 27 19:41:35 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717372, encodeId=bce51e173721a, content=<a href='/topic/show?id=2178651e5ec' target=_blank style='color:#2F92EE;'>#活动性溃疡性结肠炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65175, encryptionId=2178651e5ec, topicName=活动性溃疡性结肠炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=462a32388178, createdName=chg132, createdTime=Sat Apr 04 02:41:35 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796923, encodeId=96011e9692355, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 10 05:41:35 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810861, encodeId=08341810861ac, content=<a href='/topic/show?id=ee008640309' target=_blank style='color:#2F92EE;'>#至重度活动性溃疡性结肠炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86403, encryptionId=ee008640309, topicName=至重度活动性溃疡性结肠炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Jan 25 08:41:35 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517253, encodeId=3510151e253df, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Fri Mar 27 09:41:35 CST 2020, time=2020-03-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1695156, encodeId=ad221695156b6, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Aug 09 06:41:35 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723996, encodeId=e5a81e2399603, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Wed Jan 27 19:41:35 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717372, encodeId=bce51e173721a, content=<a href='/topic/show?id=2178651e5ec' target=_blank style='color:#2F92EE;'>#活动性溃疡性结肠炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65175, encryptionId=2178651e5ec, topicName=活动性溃疡性结肠炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=462a32388178, createdName=chg132, createdTime=Sat Apr 04 02:41:35 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796923, encodeId=96011e9692355, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 10 05:41:35 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810861, encodeId=08341810861ac, content=<a href='/topic/show?id=ee008640309' target=_blank style='color:#2F92EE;'>#至重度活动性溃疡性结肠炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86403, encryptionId=ee008640309, topicName=至重度活动性溃疡性结肠炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Jan 25 08:41:35 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517253, encodeId=3510151e253df, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Fri Mar 27 09:41:35 CST 2020, time=2020-03-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1695156, encodeId=ad221695156b6, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Aug 09 06:41:35 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723996, encodeId=e5a81e2399603, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Wed Jan 27 19:41:35 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717372, encodeId=bce51e173721a, content=<a href='/topic/show?id=2178651e5ec' target=_blank style='color:#2F92EE;'>#活动性溃疡性结肠炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65175, encryptionId=2178651e5ec, topicName=活动性溃疡性结肠炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=462a32388178, createdName=chg132, createdTime=Sat Apr 04 02:41:35 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796923, encodeId=96011e9692355, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 10 05:41:35 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810861, encodeId=08341810861ac, content=<a href='/topic/show?id=ee008640309' target=_blank style='color:#2F92EE;'>#至重度活动性溃疡性结肠炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86403, encryptionId=ee008640309, topicName=至重度活动性溃疡性结肠炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Jan 25 08:41:35 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517253, encodeId=3510151e253df, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Fri Mar 27 09:41:35 CST 2020, time=2020-03-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1695156, encodeId=ad221695156b6, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Aug 09 06:41:35 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723996, encodeId=e5a81e2399603, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Wed Jan 27 19:41:35 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717372, encodeId=bce51e173721a, content=<a href='/topic/show?id=2178651e5ec' target=_blank style='color:#2F92EE;'>#活动性溃疡性结肠炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65175, encryptionId=2178651e5ec, topicName=活动性溃疡性结肠炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=462a32388178, createdName=chg132, createdTime=Sat Apr 04 02:41:35 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796923, encodeId=96011e9692355, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 10 05:41:35 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810861, encodeId=08341810861ac, content=<a href='/topic/show?id=ee008640309' target=_blank style='color:#2F92EE;'>#至重度活动性溃疡性结肠炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86403, encryptionId=ee008640309, topicName=至重度活动性溃疡性结肠炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Jan 25 08:41:35 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517253, encodeId=3510151e253df, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Fri Mar 27 09:41:35 CST 2020, time=2020-03-27, status=1, ipAttribution=)]

相关资讯

JGH Open:克罗恩病和溃疡性结肠炎患者得憩室炎住院费用差异的比较

炎性肠病(IBD)会导致憩室炎发生的概率增加,尤其是在住院治疗中。本项研究的目的是评估与溃疡性结肠炎(UC)相比,克罗恩病(CD)患者的憩室炎的住院负担是否有所不同。

JCC:MicroRNA23a在克罗恩病中的过度表达增加了抗TNF的敏感性并保护了上皮屏障

粘膜愈合在克罗恩病治疗中很重要。克罗恩病中肠上皮稳态失调,通透性增加,炎症和腹泻增加是显着的临床表现。MicroRNA是调节基因表达并在炎症性肠病中显示变化的小型非编码RNA。

JCC:口疮性结肠炎对克罗恩病疾病结局的影响

克罗恩病[CD]中肠病变的自然病程尚未完全了解。尽管在诊断时病变的程度通常决定了疾病的程度,但在诊断时见到的某些病变,特别是口疮[AUs]样溃疡,可在随访前消退。

AP&T:维多珠单抗治疗肛周克罗恩病的疗效分析

具有肛周病变和抗TNF治疗失败的克罗恩病患者的治疗极具治疗挑战性。本项研究旨在评估维多珠单抗在肛周克罗恩病中的有效性。

JCC:克罗恩病小肠切除术后切缘炎症对术后早期内镜复发的影响

目前,人们对于克罗恩病[CD]术后早期内镜复发的发病机制和危险因素尚不清楚。因此,本研究旨在确定回肠切除术后切除边缘的组织学炎症是否影响CD内镜复发。

Clinical Trans Gastroenterology:C反应蛋白的正常化可预测克罗恩病患者粘膜愈合

克罗恩病(CD)的治疗目标已从临床和生物学缓解发展为粘膜愈合(MH)和深层缓解(DR)。MH定义为溃疡消失,而DR定义为临床缓解和MH的组合。